Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder

Inclusion Criteria: 1. Participants ≥ 18 years of age 2. Definite diagnosis according to the 2015 IPND diagnostic criteria for AQP4-IgG-positive NMOSD 3. Seropositivity for anti-AQP4 antibody. 4. Time from onset to enrollment ≤ 30 days. 5. For patients with optic neuritis: visual acuity ≤ 20/200 at screening; for relapse cases, baseline visual acuity prior to this acute episode must have been ≥ 20/60. 6. For patients with longitudinal extensive transverse myelitis (LETM): EDSS score ≥ 5.5 at screening; for relapse cases, baseline EDSS score prior to this acute episode must have been ≤ 3.5. 7. Ability to understand and voluntarily provide written informed consent- Exclusion Criteria: 1. Patients with concurrent neuromuscular disorders. 2. Patients with severe coagulation dysfunction. 3. Patients with known allergy to plasma or intravenous immunoglobulin (IVIG). 4. Patients with active hepatitis B or C virus infection, human immunodeficiency virus (HIV) infection, or those deemed at high risk for the onset or reactivation of syphilis or tuberculosis at screening. 5. Patients with active systemic infection at screening, or a history of severe chronic or recurrent infections. 6. Pregnant or lactating patients. 7. Patients with chronic, severe medical conditions that may affect study compliance. 8. Patients with any clinically significant abnormal laboratory findings as determined by the investigator (e.g., severe anemia, leukopenia, thrombocytopenia, etc.). 9. Patients whom the investigator considers unlikely to complete the study or unlikely to comply with the study requirements (for administrative reasons or otherwise).